Wellington Pham
Faculty Member
Last active: 4/2/2019

Dephosphorylation and biodistribution of 1-¹³C-phospholactate in vivo.

Shchepin RV, Pham W, Chekmenev EY
J Labelled Comp Radiopharm. 2014 57 (8): 517-24

PMID: 24995802 · PMCID: PMC4287379 · DOI:10.1002/jlcr.3207

Here, we present a new approach for the delivery of a metabolic contrast agent for in vivo molecular imaging. The use of a phosphate-protecting group that facilitates parahydrogen-induced polarization of 1-(13)C-phospholactate potentially enables the in vivo administration of a hydrogenated hyperpolarized adduct. When injected, nonhyperpolarized 1-(13)C-phospholactate is retained in the vasculature during its metabolic conversion to 1-(13)C-lactate by blood phosphatases as demonstrated here using a mucin 1 mouse model of breast cancer and ex vivo high-resolution (13)C NMR. This multisecond process is a suitable mechanism for the delivery of relatively short-lived (13)C and potentially (15)N hyperpolarized contrast agents using -OH phosphorylated small molecules, which is demonstrated here for the first time as an example of 1-(13)C-phospholactate. Through this approach, DL-1-(13)C-lactate is taken up by tissues and organs including the liver, kidneys, brain, heart, and tumors according to a timescale amenable to hyperpolarized magnetic resonance imaging.

Copyright © 2014 John Wiley & Sons, Ltd.

MeSH Terms (13)

Animals Carbon-13 Magnetic Resonance Spectroscopy Carbon Isotopes Cell Line, Tumor Contrast Media Female Lactates Lactic Acid Mammary Neoplasms, Experimental Mice Phosphorylation Radiopharmaceuticals Tissue Distribution

Connections (2)

This publication is referenced by other Labnodes entities: